Company profile
PROTARA THERAPEUTICS, INC.
NASDAQ:TARABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OK-432 | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07480356 | phase3 | recruiting | 2026-05-29 | 2028-04-01 | Protara Therapeutics | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer |
| NCT05871970 | phase2 | recruiting | 2023-10-18 | 2026-12-01 | Protara Therapeutics | Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
| NCT05951179 | phase2 | recruiting | 2023-09-15 | 2031-10-01 | Protara Therapeutics | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
| NCT05085977 | phase1 | completed | 2022-03-10 | 2024-09-03 | Protara Therapeutics | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
| NCT05085990 | phase1 | completed | 2023-05-08 | 2024-09-12 | Protara Therapeutics | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) |
FDA applications (0)
No records yet.